Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?
about
Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPThe clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.Emerging biological therapies for the treatment of myelodysplastic syndromes.
P2860
Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Risk stratification in myelody ...... for gene expression profiling?
@ast
Risk stratification in myelody ...... for gene expression profiling?
@en
Risk stratification in myelody ...... for gene expression profiling?
@nl
type
label
Risk stratification in myelody ...... for gene expression profiling?
@ast
Risk stratification in myelody ...... for gene expression profiling?
@en
Risk stratification in myelody ...... for gene expression profiling?
@nl
prefLabel
Risk stratification in myelody ...... for gene expression profiling?
@ast
Risk stratification in myelody ...... for gene expression profiling?
@en
Risk stratification in myelody ...... for gene expression profiling?
@nl
P2093
P2860
P1476
Risk stratification in myelody ...... for gene expression profiling?
@en
P2093
Amer M Zeidan
Ehab Saad Aldin
Steven David Gore
P2860
P304
P356
10.1586/17474086.2014.891437
P577
2014-02-24T00:00:00Z